Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate [indinavir] 800 mg and ritonavir 200 mg b.i.d. [twice daily] plus 2 NRTIs [nucleoside reverse transcriptase inhibitors] b.i.d. in HIV-1 infected individuals who require early treatment intervention

Next Previous
Search
Trial Profile

A multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate [indinavir] 800 mg and ritonavir 200 mg b.i.d. [twice daily] plus 2 NRTIs [nucleoside reverse transcriptase inhibitors] b.i.d. in HIV-1 infected individuals who require early treatment intervention

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indinavir (Primary) ; Nucleoside reverse transcriptase inhibitors (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 20 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top